Story
First Tracks Biotherapeutics Stock Gains After Guggenheim Initiates Coverage With $100 Target
Summary
Shares of First Tracks Biotherapeutics rose on Wednesday after investment firm Guggenheim initiated coverage with a 'Buy' rating, citing significant potential for the company's lead autoimmune drug candidate.
Shares of First Tracks Biotherapeutics Inc. (NASDAQ:TRAX) gained 3.8% in Wednesday trading after Guggenheim initiated coverage on the company with a Buy rating and a price target of $100.
Guggenheim's Bullish Thesis
In a note to clients, Guggenheim analyst Yatin Suneja expressed confidence in the company's lead asset, ANB033, and its target, anti-CD122. The firm highlighted the drug's potential across a range of autoimmune diseases.
Suneja noted that the CD122/IL-15 signaling pathway is one of the few underdeveloped targets in the autoimmunity space. According to Guggenheim, early clinical success for First Tracks' candidate in indications such as Celiac Disease, Eosinophilic Esophagitis, and Vitiligo suggests a widening therapeutic application.
Market and Scientific Context
AdThe analyst's report emphasized that First Tracks is the only publicly traded small-to-mid-cap company currently developing an anti-CD122 monoclonal antibody. This positions the company uniquely in a competitive field.
CD122, also known as IL-2Rβ/IL-15Rβ, is a receptor subunit involved in both IL-2 and IL-15 signaling. Genetic links have implicated this pathway in several autoimmune conditions, including:
- Celiac Disease
- Alopecia Areata
- Type 1 Diabetes
- Atopic Dermatitis
Guggenheim identified four major players with programs targeting the broader IL-15 and CD122 space, including two with IL-15 monoclonal antibodies and two, including First Tracks, with anti-CD122 monoclonal antibodies.
Read next
More on Stocks
U.S. Stock Futures Rebound as Markets Digest Hawkish Fed Rate Hike
U.S. stock futures rose in overnight trading, recovering from a sell-off triggered by the Federal Reserve's first interest rate hike in three years. Falling oil prices and positive corporate news helped lift market sentiment.
Holtec Suspends $900 Million IPO Amid Challenging Market Conditions
Nuclear services company Holtec Nuclear Corp. has postponed its U.S. initial public offering, which aimed to raise as much as $900 million, citing unfavorable market conditions and weak performance from recently listed peers in the sector.
Snap Stock Climbs on Enterprise Push for New Specs AR Glasses
Shares of Snap Inc. gained in after-hours trading after the company unveiled its new $2,195 Specs AR glasses and announced key enterprise partnerships with Salesforce, Nvidia, and AWS.
Gold Prices Fall as Hawkish Fed Outlook Boosts US Dollar
Gold prices declined after the Federal Reserve raised interest rates by 25 basis points and signaled further tightening, strengthening the U.S. dollar and increasing the opportunity cost of holding the non-yielding metal.